# Immuron Ltd (IMRN)

Source page: https://stoqly.net/companies/imrn

- **Ticker:** IMRN (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001660046
- **Latest annual report:** 20-F filed 2026-09-24 (https://www.sec.gov/Archives/edgar/data/1660046/000121390026102838/ea0305398-20f_immuron.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $0.88 on 2026-10-30
- **Market cap:** $6.5M
- **EPS, trailing 12 months:** −$33.61
- **Revenue (FY2026):** $5.2M
- **Revenue growth:** +10.8%
- **Revenue growth, 5-year CAGR:** +116.9%
- **Gross margin:** 64.5%
- **Operating margin:** −49.9%
- **Net margin:** −47.7%
- **Free cash flow:** −$2.2M
- **Free cash flow margin:** −42.3%
- **Return on equity:** −38.5%
- **Change in share count:** +28.6%
- **Piotroski F-score:** 3/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/imrn/figures.csv

| US$ millions | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 3 | 5 | 5 |
| Operating income | -5 | -2 | -3 | -2 | -6 | -2 | -2 | -4 | -3 | -3 |
| Net income | -5 | -2 | -3 | -2 | -6 | -2 | -3 | -5 | -3 | -2 |
| Diluted EPS (US$) | -193.02 | -71.29 | -92.10 | -44.49 | -113.11 | -36.28 | -44.66 | -79.71 | -58.51 | -33.61 |
| Operating cash flow | -5 | -3 | -1 | -2 | -3 | -2 | -2 | -4 | -4 | -2 |
| Free cash flow | -5 | -3 | -1 | -2 | -3 | -2 | -2 | -4 | — | -2 |
| Cash | 3 | 3 | 4 | 2 | 19 | 15 | 11 | 8 | 2 | 6 |
| Debt and leases | 0 | — | — | — | — | — | — | — | — | — |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.